abstract |
The present invention provides an agent for inhibiting the binding of HB-EGF and EGF receptor by binding to HB-EGF as an active ingredient, in particular, a tumor therapeutic agent comprising CRM197, wherein the tumor is a peritoneal metastatic cancer of bladder cancer, colon cancer or gastric cancer and pancreatic cancer. It is characterized in that selected from the group consisting of. |